{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T04:08:17Z","timestamp":1792382897544,"version":"4.4.0"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,4,25]],"date-time":"2021-04-25T00:00:00Z","timestamp":1619308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,25]],"date-time":"2021-04-25T00:00:00Z","timestamp":1619308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000691","name":"Academy of Medical Sciences","doi-asserted-by":"crossref","award":["SBF002\\1097"],"award-info":[{"award-number":["SBF002\\1097"]}],"id":[{"id":"10.13039\/501100000691","id-type":"DOI","asserted-by":"crossref"}]},{"name":"University of East Anglia, UK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A large proportion of patients with chronic kidney disease (CKD) are vitamin D deficient (plasma 25-hydroxyvitamin D (25(OH)D)\u2009&lt;\u200925 or 30\u00a0nmol\/L per UK and US population guidelines) and this contributes to the development of CKD\u2013mineral bone disease (CKD\u2013MBD). Gaps in the evidence-base for the management of vitamin D status in relation to CKD\u2013MBD are hindering the formulation of comprehensive guidelines. We conducted a systemic review of 22 RCTs with different forms of vitamin D or analogues with CKD\u2013MBD related outcomes and meta-analyses for parathyroid hormone (PTH). We provide a comprehensive overview of current guidelines for the management of vitamin D status for pre-dialysis CKD patients. Vitamin D supplementation had an inconsistent effect on PTH concentrations and meta-analysis showed non- significant reduction (<jats:italic>P<\/jats:italic>\u2009=\u20090.08) whereas calcifediol, calcitriol and paricalcitol consistently reduced PTH. An increase in Fibroblast Growth Factor 23 (FGF23) with analogue administration was found in all 3 studies reporting FGF23, but was unaltered in 4 studies with vitamin D or calcifediol. Few RCTS reported markers of bone metabolism and variations in the range of markers prevented direct comparisons. Guidelines for CKD stages G1\u2013G3a follow general population recommendations. For the correction of deficiency general or CKD-specific patient guidelines provide recommendations. Calcitriol or analogues administration is restricted to stages G3b\u2013G5 and depends on patient characteristics. In conclusion, the effect of vitamin D supplementation in CKD patients was inconsistent between studies. Calcifediol and analogues consistently suppressed PTH, but the increase in FGF23 with calcitriol analogues warrants caution.<\/jats:p>","DOI":"10.1007\/s00223-021-00844-1","type":"journal-article","created":{"date-parts":[[2021,4,25]],"date-time":"2021-04-25T10:08:08Z","timestamp":1619345288000},"page":"157-178","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["Vitamin D Supplementation for Patients with Chronic Kidney Disease: A Systematic Review and Meta-analyses of Trials Investigating the Response to Supplementation and an Overview of Guidelines"],"prefix":"10.1007","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5637-3768","authenticated-orcid":false,"given":"Marilena","family":"Christodoulou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9522-6069","authenticated-orcid":false,"given":"Terence J.","family":"Aspray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9246-538X","authenticated-orcid":false,"given":"Inez","family":"Schoenmakers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,25]]},"reference":[{"key":"844_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2009.188","author":"Group KDIGO (KDIGO) C-MW","year":"2009","unstructured":"Group KDIGO (KDIGO) C-MW (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. https:\/\/doi.org\/10.1038\/ki.2009.188","journal-title":"Kidney Int Suppl"},{"key":"844_CR2","doi-asserted-by":"publisher","first-page":"471","DOI":"10.7326\/0003-4819-157-7-201210020-00003","volume":"157","author":"ES Schaeffner","year":"2012","unstructured":"Schaeffner ES, Ebert N, Delanaye P et al (2012) Two novel equations to estimate kidney function in persons aged 70 years or older. Ann Intern Med 157:471. https:\/\/doi.org\/10.7326\/0003-4819-157-7-201210020-00003","journal-title":"Ann Intern Med"},{"key":"844_CR3","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1001\/jama.298.17.2038","volume":"298","author":"J Coresh","year":"2007","unstructured":"Coresh J, Selvin E, Stevens LA et al (2007) Prevalence of chronic kidney disease in the United States. JAMA 298:2038. https:\/\/doi.org\/10.1001\/jama.298.17.2038","journal-title":"JAMA"},{"key":"844_CR4","doi-asserted-by":"publisher","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","volume":"158","author":"Stevens PE, Levin A, Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members","year":"2013","unstructured":"Stevens PE, Levin A, Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members (2013) Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 158:825. https:\/\/doi.org\/10.7326\/0003-4819-158-11-201306040-00007","journal-title":"Ann Intern Med"},{"key":"844_CR5","unstructured":"Kerr M (2012) Chronic kidney disease in England: the human and financial cost"},{"key":"844_CR6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1053\/j.ajkd.2011.12.035","volume":"60","author":"SU Nigwekar","year":"2012","unstructured":"Nigwekar SU, Bhan I, Thadhani R (2012) Ergocalciferol and cholecalciferol in CKD. Am J Kidney Dis 60:139\u2013156. https:\/\/doi.org\/10.1053\/j.ajkd.2011.12.035","journal-title":"Am J Kidney Dis"},{"key":"844_CR7","doi-asserted-by":"crossref","unstructured":"Moe SM (2010) Definition and classification of renal osteodystrophy and chronic kidney disease\u2013mineral bone disorder (CKD\u2013MBD). In: The spectrum of mineral and bone disorders in chronic kidney disease. Oxford University Press, pp 1\u201314","DOI":"10.1093\/med\/9780199559176.003.001"},{"key":"844_CR8","unstructured":"SACN (2016) Vitamin D and health 2016"},{"key":"844_CR9","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1210\/jc.2011-0385","volume":"96","author":"MF Holick","year":"2011","unstructured":"Holick MF, Binkley NC, Bischoff-Ferrari HA et al (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96:1911\u20131930","journal-title":"J Clin Endocrinol Metab"},{"key":"844_CR10","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/jcsm.12264","volume":"9","author":"CM Rhee","year":"2018","unstructured":"Rhee CM, Ahmadi S-F, Kovesdy CP, Kalantar-Zadeh K (2018) Low-protein diet for conservative management of chronic kidney disease: a systematic review and meta-analysis of controlled trials. J Cachexia Sarcopenia Muscle 9:235\u2013245. https:\/\/doi.org\/10.1002\/jcsm.12264","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"844_CR11","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ecl.2010.02.002","volume":"39","author":"S Christakos","year":"2010","unstructured":"Christakos S, Ajibade DV, Dhawan P et al (2010) Vitamin D: metabolism. Endocrinol Metab Clin N Am 39:243\u201353. https:\/\/doi.org\/10.1016\/j.ecl.2010.02.002","journal-title":"Endocrinol Metab Clin N Am"},{"key":"844_CR12","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1681\/ASN.2009080815","volume":"21","author":"J Michaud","year":"2010","unstructured":"Michaud J, Naud J, Ouimet D et al (2010) Reduced hepatic synthesis of calcidiol in uremia. J Am Soc Nephrol 21:1488\u20131497. https:\/\/doi.org\/10.1681\/ASN.2009080815","journal-title":"J Am Soc Nephrol"},{"key":"844_CR13","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.tibs.2004.10.005","volume":"29","author":"D Prosser","year":"2004","unstructured":"Prosser D, Jones G (2004) Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem Sci 29:664\u2013673. https:\/\/doi.org\/10.1016\/j.tibs.2004.10.005","journal-title":"Trends Biochem Sci"},{"key":"844_CR14","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jsbmb.2012.08.008","volume":"136","author":"PH Anderson","year":"2013","unstructured":"Anderson PH, Lam NN, Turner AG et al (2013) The pleiotropic effects of vitamin D in bone. J Steroid Biochem Mol Biol 136:190\u2013194","journal-title":"J Steroid Biochem Mol Biol"},{"key":"844_CR15","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/J.KINT.2016.06.041","volume":"90","author":"P Evenepoel","year":"2016","unstructured":"Evenepoel P, Bover J, Ure\u00f1a Torres P (2016) Parathyroid hormone metabolism and signaling in health and chronic kidney disease. Kidney Int 90:1184\u20131190. https:\/\/doi.org\/10.1016\/J.KINT.2016.06.041","journal-title":"Kidney Int"},{"key":"844_CR16","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/KI.2011.47","volume":"79","author":"T Isakova","year":"2011","unstructured":"Isakova T, Wahl P, Vargas GS et al (2011) Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79:1370\u20131378. https:\/\/doi.org\/10.1038\/KI.2011.47","journal-title":"Kidney Int"},{"key":"844_CR17","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1016\/j.clinthera.2004.12.011","volume":"26","author":"ALM De Francisco","year":"2004","unstructured":"De Francisco ALM (2004) Secondary hyperparathyroidism: review of the disease and its treatment. Clin Ther 26:1976\u20131993. https:\/\/doi.org\/10.1016\/j.clinthera.2004.12.011","journal-title":"Clin Ther"},{"key":"844_CR18","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/ejcn.2012.217","volume":"67","author":"JA Alvarez","year":"2013","unstructured":"Alvarez JA, Zughaier SM, Law J et al (2013) Effects of high-dose cholecalciferol on serum markers of inflammation and immunity in patients with early chronic kidney disease. Eur J Clin Nutr 67:264\u2013269. https:\/\/doi.org\/10.1038\/ejcn.2012.217","journal-title":"Eur J Clin Nutr"},{"key":"844_CR19","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1159\/000441364","volume":"42","author":"K Lundwall","year":"2015","unstructured":"Lundwall K, J\u00f6rneskog G, Jacobson SH, Spaak J (2015) Paricalcitol, microvascular and endothelial function in non-diabetic chronic kidney disease: a randomized trial. Am J Nephrol 42:265\u2013273. https:\/\/doi.org\/10.1159\/000441364","journal-title":"Am J Nephrol"},{"key":"844_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2261-14-156","author":"A Levin","year":"2014","unstructured":"Levin A, Perry T, De Zoysa P et al (2014) A randomized control trial to assess the impact of vitamin D supplementation compared to placebo on vascular stiffness in chronic kidney disease patients. BMC Cardiovasc Disord. https:\/\/doi.org\/10.1186\/1471-2261-14-156","journal-title":"BMC Cardiovasc Disord"},{"key":"844_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-017-0436-6","author":"P Susantitaphong","year":"2017","unstructured":"Susantitaphong P, Nakwan S, Peerapornratana S et al (2017) A double-blind, randomized, placebo-controlled trial of combined calcitriol and ergocalciferol versus ergocalciferol alone in chronic kidney disease with proteinuria. BMC Nephrol. https:\/\/doi.org\/10.1186\/s12882-017-0436-6","journal-title":"BMC Nephrol"},{"key":"844_CR22","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1159\/000369939","volume":"40","author":"SM Sprague","year":"2014","unstructured":"Sprague SM, Silva AL, Al-Saghir F et al (2014) Modified-release calcifediol effectively controls secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney disease. Am J Nephrol 40:535\u2013545. https:\/\/doi.org\/10.1159\/000369939","journal-title":"Am J Nephrol"},{"key":"844_CR23","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2147\/IJNRD.S90968","volume":"8","author":"A Cupisti","year":"2015","unstructured":"Cupisti A, Egidi MF, Vigo V et al (2015) Vitamin D status and cholecalciferol supplementation in chronic kidney disease patients: an Italian cohort report. Int J Nephrol Renovasc Dis 8:151. https:\/\/doi.org\/10.2147\/IJNRD.S90968","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"844_CR24","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3945\/ajcn.112.040642","volume":"96","author":"JA Alvarez","year":"2012","unstructured":"Alvarez JA, Law J, Coakley KE et al (2012) High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 96:672\u2013679. https:\/\/doi.org\/10.3945\/ajcn.112.040642","journal-title":"Am J Clin Nutr"},{"key":"844_CR25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/j.1440-1797.2012.01662.x","volume":"18","author":"WG Petchey","year":"2013","unstructured":"Petchey WG, Hickman IJ, Prins JB et al (2013) Vitamin D does not improve the metabolic health of patients with chronic kidney disease stage 3\u20134: a randomized controlled trial. Nephrology 18:26\u201335. https:\/\/doi.org\/10.1111\/j.1440-1797.2012.01662.x","journal-title":"Nephrology"},{"key":"844_CR26","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/ki.2012.311","volume":"83","author":"IH de Boer","year":"2013","unstructured":"de Boer IH, Sachs M, Hoofnagle AN et al (2013) Paricalcitol does not improve glucose metabolism in patients with stage 3\u20134 chronic kidney disease. Kidney Int 83:323\u2013330. https:\/\/doi.org\/10.1038\/ki.2012.311","journal-title":"Kidney Int"},{"key":"844_CR27","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1161\/HYPERTENSIONAHA.108.113159","volume":"52","author":"P Alborzi","year":"2008","unstructured":"Alborzi P, Patel NA, Peterson C et al (2008) Paricalcitol reduces albuminuria and inflammation in chronic kidney disease a randomized double-blind pilot trial. Hypertension 52:249\u2013255. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.108.113159","journal-title":"Hypertension"},{"key":"844_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2369-14-163","author":"T Larsen","year":"2013","unstructured":"Larsen T, Mose FH, Bech JN, Pedersen EB (2013) Effect of paricalcitol on renin and albuminuria in non-diabetic stage III-IV chronic kidney disease: a randomized placebo-controlled trial. BMC Nephrol. https:\/\/doi.org\/10.1186\/1471-2369-14-163","journal-title":"BMC Nephrol"},{"key":"844_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0099461","author":"G Dreyer","year":"2014","unstructured":"Dreyer G, Tucker AT, Harwood SM et al (2014) Ergocalciferol and microcirculatory function in chronic kidney disease and concomitant vitamin D deficiency: an exploratory, double blind, randomised controlled trial. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0099461","journal-title":"PLoS ONE"},{"key":"844_CR30","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1001\/jama.2012.120","volume":"307","author":"R Thadhani","year":"2012","unstructured":"Thadhani R, Appelbaum E, Pritchett Y et al (2012) Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 307:674\u2013684. https:\/\/doi.org\/10.1001\/jama.2012.120","journal-title":"JAMA"},{"key":"844_CR31","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jsbmb.2018.01.007","volume":"180","author":"AK Yadav","year":"2018","unstructured":"Yadav AK, Kumar V, Banerjee D et al (2018) Effect of vitamin D supplementation on serum sclerostin levels in chronic kidney disease 180:15\u201318. https:\/\/doi.org\/10.1016\/j.jsbmb.2018.01.007","journal-title":"Effect of vitamin D supplementation on serum sclerostin levels in chronic kidney disease"},{"key":"844_CR32","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/ki.2011.224","volume":"80","author":"MJ Kim","year":"2011","unstructured":"Kim MJ, Frankel AH, Donaldson M et al (2011) Oral cholecalciferol decreases albuminuria and urinary TGF-\u03b21 in patients with type 2 diabetic nephropathy on established renin\u2013angiotensin\u2013aldosterone system inhibition. Kidney Int 80:851\u2013860. https:\/\/doi.org\/10.1038\/ki.2011.224","journal-title":"Kidney Int"},{"key":"844_CR33","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00467-015-3220-5","volume":"31","author":"MB Ayta\u00e7","year":"2016","unstructured":"Ayta\u00e7 MB, Deveci M, Bek K et al (2016) Effect of cholecalciferol on local arterial stiffness and endothelial dysfunction in children with chronic kidney disease. Pediatr Nephrol 31:267\u2013277. https:\/\/doi.org\/10.1007\/s00467-015-3220-5","journal-title":"Pediatr Nephrol"},{"key":"844_CR34","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.clnu.2016.04.014","volume":"35","author":"MS Meireles","year":"2016","unstructured":"Meireles MS, Kamimura MA, Dalboni MA et al (2016) Effect of cholecalciferol on vitamin D-regulatory proteins in monocytes and on inflammatory markers in dialysis patients: a randomized controlled trial. Clin Nutr 35:1251\u20131258. https:\/\/doi.org\/10.1016\/j.clnu.2016.04.014","journal-title":"Clin Nutr"},{"key":"844_CR35","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1159\/000098561","volume":"27","author":"AL Zisman","year":"2007","unstructured":"Zisman AL, Hristova M, Ho LT, Sprague SM (2007) Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol 27:36\u201343. https:\/\/doi.org\/10.1159\/000098561","journal-title":"Am J Nephrol"},{"key":"844_CR36","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1053\/J.AJKD.2007.04.010","volume":"50","author":"Z Al-Aly","year":"2007","unstructured":"Al-Aly Z, Qazi RA, Gonz\u00e1lez EA et al (2007) Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD. Am J Kidney Dis 50:59\u201368. https:\/\/doi.org\/10.1053\/J.AJKD.2007.04.010","journal-title":"Am J Kidney Dis"},{"key":"844_CR37","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1172\/JCI111639","volume":"74","author":"E Slatopolsky","year":"1984","unstructured":"Slatopolsky E, Weerts C, Thielan J et al (1984) Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 74:2136\u20132143. https:\/\/doi.org\/10.1172\/JCI111639","journal-title":"J Clin Invest"},{"key":"844_CR38","doi-asserted-by":"publisher","first-page":"774","DOI":"10.7326\/0003-4819-88-6-774","volume":"88","author":"T Berl","year":"1978","unstructured":"Berl T, Berns AS, Hufer WE et al (1978) 1,25 dihydroxycholecalciferol effects in chronic dialysis. A double-blind controlled study. Ann Intern Med 88:774\u2013780. https:\/\/doi.org\/10.7326\/0003-4819-88-6-774","journal-title":"Ann Intern Med"},{"key":"844_CR39","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1159\/000346791","volume":"180","author":"M Koizumi","year":"2013","unstructured":"Koizumi M, Komaba H, Fukagawa M (2013) Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis. Contrib Nephrol 180:110\u2013123. https:\/\/doi.org\/10.1159\/000346791","journal-title":"Contrib Nephrol"},{"key":"844_CR40","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1097\/01.BRS.0000065484.95996.AF","volume":"28","author":"M van Tulder","year":"2003","unstructured":"van Tulder M, Furlan A, Bombardier C et al (2003) Updated method guidelines for systematic reviews in the cochrane collaboration back review group. Spine 28:1290\u20139. https:\/\/doi.org\/10.1097\/01.BRS.0000065484.95996.AF","journal-title":"Spine"},{"key":"844_CR41","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1080\/08860220801964210","volume":"30","author":"E Dogan","year":"2008","unstructured":"Dogan E, Erkoc R, Sayarlioglu H et al (2008) Effect of depot oral cholecalciferol treatment on secondary hyperparathyroidism in stage 3 and stage 4 chronic kidney diseases patients. Ren Fail 30:407\u2013410. https:\/\/doi.org\/10.1080\/08860220801964210","journal-title":"Ren Fail"},{"key":"844_CR42","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1159\/000157177","volume":"31","author":"A Ok\u0161a","year":"2008","unstructured":"Ok\u0161a A, Spustov\u00e1 V, Krivo\u0161\u00edkov\u00e1 Z et al (2008) Effects of long-term cholecalciferol supplementation on mineral metabolism and calciotropic hormones in chronic kidney disease. Kidney Blood Press Res 31:322\u2013329. https:\/\/doi.org\/10.1159\/000157177","journal-title":"Kidney Blood Press Res"},{"key":"844_CR43","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2215\/CJN.07131009","volume":"5","author":"SM Moe","year":"2010","unstructured":"Moe SM, Saifullah A, LaClair RE et al (2010) A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease. Clin J Am Soc Nephrol 5:299\u2013306. https:\/\/doi.org\/10.2215\/CJN.07131009","journal-title":"Clin J Am Soc Nephrol"},{"key":"844_CR44","doi-asserted-by":"publisher","first-page":"10","DOI":"10.4158\/EP.14.1.10","volume":"14","author":"P Chandra","year":"2008","unstructured":"Chandra P, Binongo JNG, Ziegler TR et al (2008) Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: a randomized controlled pilot study. Endocr Pract 14:10\u201317. https:\/\/doi.org\/10.4158\/EP.14.1.10","journal-title":"Endocr Pract"},{"key":"844_CR45","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1093\/ndt\/gfx059","volume":"33","author":"A Westerberg","year":"2018","unstructured":"Westerberg A, Sterner G, Ljunggren O et al (2018) High doses of cholecalciferol alleviate the progression of hyperparathyroidism in patients with CKD Stages 3\u20134: results of a 12-week double-blind, randomized, controlled study. Nephrol Dial Transpl 33:466\u2013471. https:\/\/doi.org\/10.1093\/ndt\/gfx059","journal-title":"Nephrol Dial Transpl"},{"key":"844_CR46","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1053\/j.ajkd.2011.06.027","volume":"59","author":"CP Kovesdy","year":"2012","unstructured":"Kovesdy CP, Lu JL, Malakauskas SM et al (2012) Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: a randomized controlled trial. Am J Kidney Dis 59:58\u201366. https:\/\/doi.org\/10.1053\/j.ajkd.2011.06.027","journal-title":"Am J Kidney Dis"},{"key":"844_CR47","doi-asserted-by":"crossref","unstructured":"Petkovich M. BCW (2018) Vitamin D: Volume 1: Biochemistry, Physiology and Diagnostics. In: David F, Wesley PJ, Roger B, Edward G, David HMG (eds), 4th edn. Elsevier, pp 667\u2013678","DOI":"10.1016\/B978-0-12-809963-6.00091-2"},{"key":"844_CR48","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jsbmb.2014.11.022","volume":"148","author":"M Petkovich","year":"2015","unstructured":"Petkovich M, Melnick J, White J et al (2015) Modified-release oral calcifediol corrects vitamin D insufficiency with minimal CYP24A1 upregulation. J Steroid Biochem Mol Biol 148:283\u2013289. https:\/\/doi.org\/10.1016\/j.jsbmb.2014.11.022","journal-title":"J Steroid Biochem Mol Biol"},{"key":"844_CR49","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1159\/000450766","volume":"44","author":"SM Sprague","year":"2016","unstructured":"Sprague SM, Crawford PW, Melnick JZ et al (2016) Use of extended-release calcifediol to treat secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. Am J Nephrol 44:316\u2013325. https:\/\/doi.org\/10.1159\/000450766","journal-title":"Am J Nephrol"},{"key":"844_CR50","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.2215\/CJN.10791016","volume":"12","author":"A Levin","year":"2017","unstructured":"Levin A, Tang M, Perry T et al (2017) Randomized controlled trial for the effect of vitamin D supplementation on vascular stiffness in CKD. Clin J Am Soc Nephrol 12:1447\u20131460. https:\/\/doi.org\/10.2215\/CJN.10791016","journal-title":"Clin J Am Soc Nephrol"},{"key":"844_CR51","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/ki.2008.166","volume":"74","author":"P Evenepoel","year":"2008","unstructured":"Evenepoel P (2008) Calcimimetics in chronic kidney disease: evidence, opportunities and challenges. Kidney Int 74:265\u2013275. https:\/\/doi.org\/10.1038\/ki.2008.166","journal-title":"Kidney Int"},{"key":"844_CR52","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1172\/JCI111639","volume":"74","author":"E Slatopolsky","year":"1984","unstructured":"Slatopolsky E, Weerts C, Thielan J et al (1984) Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest 74:2136\u20132143. https:\/\/doi.org\/10.1172\/JCI111639","journal-title":"J Clin Invest"},{"key":"844_CR53","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/S0140-6736(10)61032-X","volume":"376","author":"D De Zeeuw","year":"2010","unstructured":"De Zeeuw D, Agarwal R, Amdahl M et al (2010) Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 376:1543\u20131551. https:\/\/doi.org\/10.1016\/S0140-6736(10)61032-X","journal-title":"Lancet"},{"key":"844_CR54","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1681\/ASN.2013010103","volume":"25","author":"AYM Wang","year":"2014","unstructured":"Wang AYM, Fang F, Chan J et al (2014) Effect of paricalcitol on left ventricular mass and function in CKD-The OPERA trial. J Am Soc Nephrol 25:175\u2013186. https:\/\/doi.org\/10.1681\/ASN.2013010103","journal-title":"J Am Soc Nephrol"},{"key":"844_CR55","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1161\/HYPERTENSIONAHA.114.03748","volume":"64","author":"C Zoccali","year":"2014","unstructured":"Zoccali C, Curatola G, Panuccio V et al (2014) Paricalcitol and endothelial function in chronic kidney disease trial. Hypertension 64:1005\u20131011. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.114.03748","journal-title":"Hypertension"},{"key":"844_CR56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0118174","author":"E Riccio","year":"2015","unstructured":"Riccio E, Sabbatini M, Bruzzese D et al (2015) Effect of paricalcitol vs calcitriol on hemoglobin levels in chronic kidney disease patients: a randomized trial. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0118174","journal-title":"PLoS ONE"},{"key":"844_CR57","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1053\/j.ajkd.2005.10.007","volume":"47","author":"D Coyne","year":"2006","unstructured":"Coyne D, Acharya M, Qiu P et al (2006) Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis 47:263\u2013276. https:\/\/doi.org\/10.1053\/j.ajkd.2005.10.007","journal-title":"Am J Kidney Dis"},{"key":"844_CR58","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.2215\/CJN.10661013","volume":"9","author":"DW Coyne","year":"2014","unstructured":"Coyne DW, Goldberg S, Faber M et al (2014) A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3\u20134 CKD. Clin J Am Soc Nephrol 9:1620\u20131626. https:\/\/doi.org\/10.2215\/CJN.10661013","journal-title":"Clin J Am Soc Nephrol"},{"key":"844_CR59","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1017\/S0007114515003189","volume":"114","author":"N Moslehi","year":"2013","unstructured":"Moslehi N, Shab-Bidar S, Mirmiran P et al (2013) Determinants of parathyroid hormone response to Vitamin D supplementation: a systematic review and meta-analysis of randomised controlled trials. Br J Nutr 114:1360\u20131374. https:\/\/doi.org\/10.1017\/S0007114515003189","journal-title":"Br J Nutr"},{"key":"844_CR60","unstructured":"Cranney A, Horsley T, O\u2019Donnell S, et al (2007) Effectiveness and safety of vitamin D in relation to bone health. Agency for Healthcare Research and Quality (US)"},{"key":"844_CR61","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1359\/JBMR.0301264","volume":"19","author":"T Shimada","year":"2003","unstructured":"Shimada T, Hasegawa H, Yamazaki Y et al (2003) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19:429\u2013435. https:\/\/doi.org\/10.1359\/JBMR.0301264","journal-title":"J Bone Miner Res"},{"key":"844_CR62","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1681\/asn.2013050465","volume":"12","author":"R Middleton","year":"2014","unstructured":"Middleton R, Parfrey P, Foley R et al (2014) Left ventricular hypertrophy in the renal patient. J Am Soc Nephrol 12:1079\u20131084. https:\/\/doi.org\/10.1681\/asn.2013050465","journal-title":"J Am Soc Nephrol"},{"key":"844_CR63","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s11906-010-0142-2","volume":"12","author":"MR Lattanzio","year":"2010","unstructured":"Lattanzio MR, Weir MR (2010) Does blockade of the renin-angiotensin-aldosterone system slow progression of all forms of kidney disease? Curr Hypertens Rep 12:369\u2013377. https:\/\/doi.org\/10.1007\/s11906-010-0142-2","journal-title":"Curr Hypertens Rep"},{"key":"844_CR64","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1007\/s00198-019-05102-7","volume":"30","author":"N Charoenngam","year":"2019","unstructured":"Charoenngam N, Rujirachun P, Holick MF, Ungprasert P (2019) Oral vitamin D3 supplementation increases serum fibroblast growth factor 23 concentration in vitamin D-deficient patients: a systematic review and meta-analysis. Osteoporos Int 30:2183\u20132193","journal-title":"Osteoporos Int"},{"key":"844_CR65","doi-asserted-by":"publisher","first-page":"10","DOI":"10.5414\/cnp70010","volume":"70","author":"R Hojs","year":"2008","unstructured":"Hojs R, Bevc S, Ekart R et al (2008) Serum crystatin C-based equation compared to serum creatinine-based equations for estimation of glomerular filtration rate in patient with chronic kidney disease. Clin Nephrol 70:10\u201317. https:\/\/doi.org\/10.5414\/cnp70010","journal-title":"Clin Nephrol"},{"key":"844_CR66","unstructured":"National Kidney Foundation (2009) Cystatin C"},{"key":"844_CR67","unstructured":"NICE (2019) Chronic kidney disease - NICE CKS. https:\/\/cks.nice.org.uk\/chronic-kidney-disease#!scenario. Accessed 4 Dec 2019"},{"key":"844_CR68","unstructured":"National Institute for Clinical Excellence (2015) Chronic kidney disease in adults: assessment and management. NICE"},{"key":"844_CR69","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1093\/ageing\/afj041","volume":"35","author":"C Pedone","year":"2006","unstructured":"Pedone C, Corsonello A, Incalzi RA (2006) Estimating renal function in older people: a comparison of three formulas. Age Ageing 35:121\u2013126. https:\/\/doi.org\/10.1093\/ageing\/afj041","journal-title":"Age Ageing"},{"key":"844_CR70","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/J.NEFROE.2015.05.006","volume":"35","author":"C Yuste","year":"2015","unstructured":"Yuste C, Quiroga B, Garc\u00eda de Vinuesa S et al (2015) The effect of some medications given to CKD patients on vitamin D levels. Nefrol 35:150\u2013156. https:\/\/doi.org\/10.1016\/J.NEFROE.2015.05.006","journal-title":"Nefrol"},{"key":"844_CR71","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.cct.2011.09.009","volume":"33","author":"JE Manson","year":"2012","unstructured":"Manson JE, Bassuk SS, Lee I-M et al (2012) The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials 33:159\u2013171. https:\/\/doi.org\/10.1016\/j.cct.2011.09.009","journal-title":"Contemp Clin Trials"},{"key":"844_CR72","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/kisup.2011.30","volume":"1","author":"AS Dusso","year":"2011","unstructured":"Dusso AS (2011) Kidney disease and vitamin D levels: 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and VDR activation. Kidney Int Suppl 1:136\u2013141. https:\/\/doi.org\/10.1038\/kisup.2011.30","journal-title":"Kidney Int Suppl"},{"key":"844_CR73","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.nefroe.2016.11.010","volume":"36","author":"F Caravaca-Font\u00e1n","year":"2016","unstructured":"Caravaca-Font\u00e1n F, Gonzales-Candia B, Luna E, Caravaca F (2016) Relative importance of the determinants of serum levels of 25-hydroxy vitamin D in patients with chronic kidney disease. Nefrol 36:510\u2013516. https:\/\/doi.org\/10.1016\/j.nefroe.2016.11.010","journal-title":"Nefrol"},{"key":"844_CR74","doi-asserted-by":"publisher","first-page":"9","DOI":"10.18773\/austprescr.2017.002","volume":"40","author":"S Chan","year":"2017","unstructured":"Chan S, Au K, Francis RS et al (2017) Phosphate binders in patients with chronic kidney disease. Aust Prescr 40:9\u201314","journal-title":"Aust Prescr"},{"key":"844_CR75","first-page":"1","volume":"42","author":"National Kidney Foundation","year":"2003","unstructured":"National Kidney Foundation (2003) K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42:1\u2013202","journal-title":"Am J Kidney Dis"},{"key":"844_CR76","volume-title":"Vitamin D","author":"D Feldman","year":"2018","unstructured":"Feldman D (2018) Vitamin D, vol 2. Academic Press, Health, Disease and Therapeutics"},{"key":"844_CR77","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1093\/ndt\/gfaa010","volume":"35","author":"C Ginsberg","year":"2020","unstructured":"Ginsberg C, Zelnick LR, Block GA et al (2020) Differential effects of phosphate binders on vitamin D metabolism in chronic kidney disease. Nephrol Dial Transpl 35:616\u2013623. https:\/\/doi.org\/10.1093\/ndt\/gfaa010","journal-title":"Nephrol Dial Transpl"},{"key":"844_CR78","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/nrendo.2017.31","volume":"13","author":"R Bouillon","year":"2017","unstructured":"Bouillon R (2017) Comparative analysis of nutritional guidelines for vitamin D. Nat Rev Endocrinol 13:466\u2013479","journal-title":"Nat Rev Endocrinol"},{"key":"844_CR79","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1530\/EJE-18-0736","volume":"180","author":"P Lips","year":"2019","unstructured":"Lips P, Cashman KD, Lamberg-Allardt C, Bischoff-Ferrari HA, Obermayer-Pietsch B, Bianchi ML, Stepan J et al (2019) Current vitamin D status in European and Middle East countries and strategies to prevent vitamin D deficiency: a position statement of the European Calcified Tissue Society. Eur J Endocrinol 180:23\u201354. https:\/\/doi.org\/10.1530\/EJE-18-0736","journal-title":"Eur J Endocrinol"},{"key":"844_CR80","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1210\/jc.2010-2704","volume":"96","author":"AC Ross","year":"2011","unstructured":"Ross AC, Manson JAE, Abrams SA et al (2011) The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 96:53\u201358","journal-title":"J Clin Endocrinol Metab"},{"key":"844_CR81","doi-asserted-by":"publisher","unstructured":"European Food Safety Authority (EFSA) (2017) Technical Report dietary reference values for nutrients summary report. https:\/\/doi.org\/10.2903\/sp.efsa.2017.e15121","DOI":"10.2903\/sp.efsa.2017.e15121"},{"key":"844_CR82","unstructured":"IOM (Institute of Medicine) (2011) Dietary reference intakes for calcium and vitamin D"},{"key":"844_CR83","unstructured":"Vitamin D deficiency in adults - treatment and prevention - NICE CKS. https:\/\/cks.nice.org.uk\/vitamin-d-deficiency-in-adults-treatment-and-prevention#!scenario. Accessed 4 Dec 2019"},{"key":"844_CR84","unstructured":"National Kidney Foundation (2016) A clinical update on vitamin D deficiency and secondary hyperparathyroidism: vitamin D testing and supplementation in CKD stages 3\u20134 part 2"},{"key":"844_CR85","unstructured":"Francis R, Aspray T, Fraser W, Macdonald H, Patel S, Mavroeidi A, Schoenmakers I (2018) Vitamin D and bone health: a practical clinical guideline for patient management. R Osteoporos Soc 1\u201325"},{"key":"844_CR86","unstructured":"Chan M, Johnson D (2012) Vitamin D therapy (supplementation) in early chronic kidney disease"},{"key":"844_CR87","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/nep.12052","volume":"18","author":"DW Johnson","year":"2013","unstructured":"Johnson DW, Atai E, Chan M et al (2013) KHA-CARI guideline: early chronic kidney disease: detection, prevention and management. Nephrology 18:340\u2013350. https:\/\/doi.org\/10.1111\/nep.12052","journal-title":"Nephrology"},{"key":"844_CR88","unstructured":"Kidney Health Australia (2015) Chronic kidney disease (CKD) management in general practice, 4th ed. Melbourne"},{"key":"844_CR89","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1053\/j.ajkd.2017.07.019","volume":"70","author":"T Isakova","year":"2017","unstructured":"Isakova T, Nickolas TL, Denburg M et al (2017) KDOQI US commentary on the 2017 KDIGO clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Am J Kidney Dis 70:737\u2013751. https:\/\/doi.org\/10.1053\/j.ajkd.2017.07.019","journal-title":"Am J Kidney Dis"},{"key":"844_CR90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","volume":"7","author":"KDIGO","year":"2017","unstructured":"KDIGO (2017) KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 7:1\u201359. https:\/\/doi.org\/10.1016\/j.kisu.2017.04.001","journal-title":"Kidney Int Suppl"},{"key":"844_CR91","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1210\/jc.2012-1238","volume":"97","author":"P Autier","year":"2012","unstructured":"Autier P, Gandini S, Mullie P (2012) A systematic review: Influence of vitamin D supplementation on serum 25-hydroxyvitamin D concentration. J Clin Endocrinol Metab 97:2606\u20132613","journal-title":"J Clin Endocrinol Metab"},{"key":"844_CR92","doi-asserted-by":"crossref","unstructured":"Heaney RP, Armas LA, Shary JR, et al (2008) 25-Hydroxylation of vitamin D 3: relation to circulating vitamin D 3 under various input conditions 1\u20133","DOI":"10.1093\/ajcn\/87.6.1738"},{"key":"844_CR93","doi-asserted-by":"publisher","first-page":"495","DOI":"10.3122\/jabfm.2014.04.130306","volume":"27","author":"G Singh","year":"2014","unstructured":"Singh G, Bonham AJ (2014) A predictive equation to guide vitamin D replacement dose in patients. J Am Board Fam Med 27:495\u2013509. https:\/\/doi.org\/10.3122\/jabfm.2014.04.130306","journal-title":"J Am Board Fam Med"},{"key":"844_CR94","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1017\/S0007114511005058","volume":"106","author":"KD Cashman","year":"2011","unstructured":"Cashman KD, Fitzgerald AP, Kiely M, Seamans KM (2011) A systematic review and meta-regression analysis of the vitamin D intake-serum 25-hydroxyvitamin D relationship to inform European recommendations. Br J Nutr 106:1638\u20131648","journal-title":"Br J Nutr"},{"key":"844_CR95","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.metabol.2014.04.009","volume":"63","author":"M Hoteit","year":"2014","unstructured":"Hoteit M, Al-Shaar L, Yazbeck C et al (2014) Hypovitaminosis D in a sunny country: time trends, predictors, and implications for practice guidelines. Metabolism 63:968\u2013978. https:\/\/doi.org\/10.1016\/j.metabol.2014.04.009","journal-title":"Metabolism"},{"key":"844_CR96","unstructured":"SCAN (2016) Vitamin D and health 2016"},{"key":"844_CR97","unstructured":"Food Safety Authority of Ireland (1999) Recommended dietary allowances for Ireland: 1999"},{"key":"844_CR98","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/nbu.12108","volume":"39","author":"A Spiro","year":"2014","unstructured":"Spiro A, Buttriss JL (2014) Vitamin D: an overview of vitamin D status and intake in Europe. Nutr Bull 39:322\u2013350. https:\/\/doi.org\/10.1111\/nbu.12108","journal-title":"Nutr Bull"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-021-00844-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-021-00844-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-021-00844-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T03:11:56Z","timestamp":1626059516000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-021-00844-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,25]]},"references-count":98,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["844"],"URL":"https:\/\/doi.org\/10.1007\/s00223-021-00844-1","relation":{},"ISSN":["0171-967X","1432-0827"],"issn-type":[{"value":"0171-967X","type":"print"},{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,25]]},"assertion":[{"value":"10 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors Marilena Christodoulou, Terence J. Aspray and Inez Schoenmakers declare that they have no conflict of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}